Watchman Left Atrial Appendage Closure (LAAC) Implant
A Life Changing Stroke Treatment Option
Led by our advanced team of cardiologists, the Cardiovascular Program at Jersey Shore University Medical Center now offers the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, a life changing stroke risk treatment option. The WATCHMAN™ LAAC Device is a first-of-its-kind, proven alternative to long-term warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.
Riple J. Hansalia, M.D. discusses the WATCHMAN device on NJ 101.5
For patients with non-valvural atrial fibrillation considered suitable for warfarin by their physicians, but have reason to seek an alternative, the WATCHMAN™ LAAC Device is an implant-based alternative to warfarin. The WATCHMAN™ LAAC Device is implanted in the left atrial appendage of your heart to permanently close off this small pouch and keep harmful blood clots from entering your bloodstream. By closing off the left atrial appendage, the source of more than 90% of stroke-causing blood clots that come from the heart in people with non-valvular AF5, the risk of stroke may be reduced and, over time, you may be able to stop taking warfarin.
Brett Sealove, M.D. and Ashish Patel, M.D. part of Meridian Cardiovascular Network, discuss a life changing stroke risk treatment option called the Watchman ™device.
The Only Proven LAAC Device
The Watchman device demonstrated comparable stroke risk reduction, and statistically superior reductions in hemorrhagic stroke, disabling stroke and cardiovascular death compared to warfarin over long-term follow-up.*
• 85% in hemorrhagic stroke
• 63% in disabling stroke
• 56% in cardiovascular death
*PROTECT AF. Relative risk reductions in hemorrhagic stroke and CV death at 5 yrs, disabling stroke at 4 yrs
• After 45 days, most patients were able to stop taking warfarin, and over 99% were off of warfarin at 1 year.*
*After per-protocol cessation of anti-thrombotics by WATCHMAN patients. Source: Price MJ. Avoidance of Major Bleeding with WATCHMAN LAA Closure Compared with Long-Term Anticoagulation: A Pooled analysis of PROTECT AF and PREVAIL trials. TCT 2014
• Patients treated with the Wathman therapy had a 71% relative reduction in major bleeding after six months compared to patients treated with warfarin.*
Meet Our Team
|Riple J. Hansalia, M.D.
|Ashish B. Patel, M.D.
|Brett A. Sealove, M.D.
- Jersey Shore University Medical Center, 1945 Route 33, Neptune, NJ 07753
Find a Physician
Looking for a physician in your area? By using our Physician Directory, you can search for a New Jersey physician by specialty, facility, town, and zip code right now.
For more information on any physician, call 1-800-DOCTORS or 1-800-560-9990.